AI startup Cohere has doubled its annualized revenue since the beginning of the year, reaching US$100 million as of May 2025.

The growth is driven by demand for customized AI tools in regulated sectors like finance, healthcare, and government.

The company shifted its focus in late 2024 to private deployments for enterprise clients.

Around 85% of its revenue now comes from these deployments, with profit margins reported at 80%. Most of the revenue is from long-term contracts.

In January 2025, Cohere launched “North,” an AI tool for knowledge workers, now in limited testing with clients such as Royal Bank of Canada and LG.

Cohere has raised over US$900 million from backers like Nvidia, Cisco, and Inovia Capital. It was last valued at US$5.5 billion.

🔗 Source: Reuters

🧠 Food for thought

1️⃣ Enterprise-focused strategy drives rapid revenue acceleration

Cohere’s pivot to specialized private deployments has produced remarkable results, with revenue jumping from $13 million in 2023 to $100 million by May 2025, a nearly 8x increase in less than two years 1.

The company’s strategic shift toward tailored solutions for regulated industries like finance and healthcare (rather than competing in the consumer AI space) has yielded exceptional unit economics, with 85% of business now coming from private deployments carrying 80% margins 2.

This contrasts with consumer-focused AI companies that often struggle with monetization despite technological prowess, highlighting how enterprise-specific positioning can create clearer paths to profitability in the AI sector.

Cohere’s Command A model achieving GPT-4-comparable capabilities at lower costs has resonated with enterprise customers seeking both performance and efficiency 3, enabling the company to win notable clients including Royal Bank of Canada, Oracle, and Fujitsu.

2️⃣ AI valuation metrics evolving as the market matures

Cohere’s valuation progression reveals how investor frameworks for AI companies are shifting toward revenue fundamentals rather than purely technological potential.

The company’s valuation grew from $2.2 billion in June 2023 to $5.5 billion in July 2024, representing a multiple decrease from roughly 169x annual revenue ($13M) to 157x revenue ($35M) during this period 45.